GB Sciences awaits drug data, WeedMD mixes acquisition & advocacy, Cresco & Organigram raise capital and more

Cannabis companies continue to look for ways to raise capital and customer counts.

Here are some of the key headlines from this past week:

  • GB Sciences building cash reserves for potential FDA trials
  • Organigram and Cresco announce stock sale programs
  • WeedMD mixes acquisition, advocacy
  • Akerna acquisition details
  • Investor Intelligence Conference and MJBizCon Next Week!

Read Now

Sign inJoin for instant access